Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223632 · ClinicalTrials.gov registry record · Phase 1
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
A Phase 1 study of Neuromuscular Diseases (NMD) and Charcot Marie Tooth Disease (CMT), sponsored by Vanda Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT07223632: Active Phase 1 study of Neuromuscular Diseases (NMD) and Charcot Marie Tooth Disease (CMT), sponsored by Vanda Pharmaceuticals.
NCT07223632 is a Phase 1 study of Neuromuscular Diseases (NMD) and Charcot Marie Tooth Disease (CMT) that is active but no longer recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 1 participants, below the 858-participant average among 3 other Neuromuscular Diseases (NMD) trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223632, a Phase 1 study of Neuromuscular Diseases (NMD) and Charcot Marie Tooth Disease (CMT), is active but no longer recruiting, sponsored by Vanda Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an 'N of 1', open-label, single center study to evaluate the safety of therapy with VCA-894A, an ASO designed to rescue and restore the activity of IGHMBP2, when administered by intrathecal injection.
Primary Outcome
Safety will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with VCA-894A.
Conditions Studied
Interventions
- DRUG VCA-894A
Study Locations (1)
Wisconsin
- Vanda Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT07223632 still lists
NCT07223632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 858-participant average among 3 other Neuromuscular Diseases (NMD) trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Neuromuscular Diseases (NMD) appearing as the primary indexed condition, and to 1 intervention - of which VCA-894A is the first listed.
NCT07223632 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07223632 about?
NCT07223632 is a clinical study titled "Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient". This is an 'N of 1', open-label, single center study to evaluate the safety of therapy with VCA-894A, an ASO designed to rescue and restore the activity of IGHMBP2, when administered by intrathecal injection.
What is the current status of trial NCT07223632?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-05-13. Estimated completion is 2026-03.
What conditions does trial NCT07223632 study?
This clinical trial studies the following conditions: Neuromuscular Diseases (NMD), Charcot Marie Tooth Disease (CMT).
What interventions are being tested in trial NCT07223632?
The interventions under investigation include: VCA-894A (DRUG).
Who is sponsoring clinical trial NCT07223632?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223632 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromuscular Diseases (NMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI